The UK and US have announced a major commercial pact that will preserve no import taxes on British pharmaceutical products going into the US market.
The Terms of the Deal
As part of the deal, the UK has pledged to boost funding on medicines through the NHS. This commitment guarantees that duties on these crucial goods will stay at zero for a period of three years.
This deal comes after earlier statements to significantly raise tariffs on patented drug imports, with figures discussed reaching double the cost.
"This arrangement with the UK strengthens the international landscape for innovative medicines and establishes long-overdue fairness to American-British pharmaceutical trade," a release noted.
Trade Importance
Pharmaceuticals are one of the UK's biggest exports to the United States, which is clearly the biggest buyer for major UK drugmakers.
Trade data indicate that in the year prior to the third quarter, the UK shipped drugs worth over eleven billion pounds to the US. This amount accounted for a significant portion of British export trade in that span.
"This deal secures employment, stimulates investment and facilitates the UK to establish itself as a global hub for biotech and pharma," a minister commented.
Key UK Commitments
The agreement involves several notable commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it considers new treatments to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a target to raise overall health service expenditure on drugs from 0.3% of GDP to 0.6% over the coming ten years.
- Rebate Cap: The sum manufacturers must pay back to the NHS to control costs will be limited at 15%. Previously, refunds exceeded 20%.
Recent Tensions
The pact comes amid a ongoing tension between the sector and the UK government over medicine costs and NHS adoption.
This friction were heightened by assertions that American consumers were paying a premium for the same drugs than people in the Britain and the EU.
Recently, several significant drug company projects in the UK have been delayed or scrapped, while major expansions have been pledged toward projects in the United States.
A senior figure publicly accepted that the NHS must spend more on treatments, noting that its spending on drugs had declined as a percentage of its overall budget over the last ten years.
